Poor countries desperately need better access to generic medicines
As the Access to Medicine Foundation publishes the first ever analytical framework specifically for generic and biosimilar medicine manufacturers, Jayasree Iyer, CEO, writes for the Financial Times about why this is important.
The piece describes the opportunities that are available to generics companies and the need for them to make a conscious effort to address global health challenges and realise their potential as key players in access to medicine.
"We know this is possible, because generics companies are already experts at delivering lower-cost treatments at scale, and have stepped up previously to address urgent issues."
Read the article on the Financial Times website.